Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis

BMC Gastroenterology

Volumn 16, Issue 1, 2016, Pages

  Zhang, Yan ^a   Li, Lixiang ^a   Guo, Chuanguo ^a   Mu, Dan ^a   Feng, Bingcheng ^a   Zuo, Xiuli ^a   Li, Yanqing ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Irritable bowel syndrome; Meta analysis; Probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT; GAS;

ABDOMINAL PAIN; ARTICLE; BACILLUS COAGULANS; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BLOATING; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DRUG MEGADOSE; DRUG RESPONSE; ENTEROCOCCUS FAECIUM; HUMAN; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LOW DRUG DOSE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PEDIOCOCCUS ACIDILACTICI; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROME III CRITERIA; SACCHAROMYCES BOULARDII; SINGLE DRUG DOSE; STREPTOCOCCUS THERMOPHILUS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; COMPLICATION; DRUG ADMINISTRATION; GAS; INTESTINE; IRRITABLE BOWEL SYNDROME; PATHOPHYSIOLOGY; PHYSIOLOGY;

ABDOMINAL PAIN; DRUG ADMINISTRATION SCHEDULE; GASES; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; PROBIOTICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84978062576     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-016-0470-z     Document Type: Article

References (54)

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterol Assoc. 2012;10(7):712-21. e4.
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-1491.
3. Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther. 2014;39(10):1033-42.
4. Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol. 2015;12(1):36-49.
5. Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014;20(27):8859-66.
6. Hussain Z, Quigley EM. Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23(4):465-71.
7. Jarcho JM, Chang L, Berman M, Suyenobu B, Naliboff BD, Lieberman MD, et al. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. Aliment Pharmacol Ther. 2008;28(3):344-52.
8. Jones R. Treatment of irritable bowel syndrome in primary care. BMJ. 2008;337:a2213.
9. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313.
10. Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J Gastroenterol. 2013;19(36):5973-80.
11. Bohn L, Storsrud S, Liljebo T, Collin L, Lindfors P, Tornblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399-407. e2.
12. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
13. FAO/WHO Working Group Guidelines for the evaluation of probiotics in food. London, Ontario, Canada. Available at ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.
14. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-62.
15. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome - focus on lactic acid bacteria. Aliment Pharmacol Ther. 2012;35(4):403-13.
16. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072-84.
17. Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med (Tokyo, Japan). 2015;54(3):243-9.
18. Nikfar S, Mozafari S, Didari T, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: a systematic review with meta-analysis. Value Health. 2014;17(7):A363.
19. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-32.
20. Ortiz-Lucas M, Tobias A, Saz P, Sebastian JJ. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Rev Esp Enferm Dig. 2013;105(1):19-36.
21. Drossman DA, Rome DDL, III. New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):237.
22. Drossman DA. The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment: a multinational consenus: little brown. 1994.
23. Drossman DA. Rome II: the functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment: a multinational consensus: Degnon Associates Incorporated. 2000.
24. Manning A, Thompson WG, Heaton K, Morris A. Towards positive diagnosis of the irritable bowel. BMJ. 1978;2(6138):653-4.
25. Sperber A D, Shvartzman P, Friger M, Fich A. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the 'true'prevalence of irritable bowel syndrome?. European journal of gastroenterology & hepatology. 2007;19(6):441-447.
26. Whelan K. Editorial: the importance of systematic reviews and meta-analyses of probiotics and prebiotics. Am J Gastroenterol. 2014;109(10):1563-5.
27. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
29. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
30. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008;53(10):2714-8.
31. Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver. 2009;3(2):101-7. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/611/CN-01044611/frame.html.
32. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(10):1123-32.
33. Michail S, Kenche H. Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL#3 in diarrhea-predominant irritable bowel syndrome. Probiotics Antimicrob Proteins. 2011;3(1):1-7.
34. Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G, et al. Probiotic bacteria lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol. 2011;45(6):518-25.
35. Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol. 2012;18(17):2067-75.
36. Ducrotte P, Sawant P, Jayanthi V. Clinical trial: lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-8.
37. Cui S, Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int J Clin Exp Med. 2012;5(3):238-44.
38. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol. 2012;46(3):220-7.
39. Amirimani B, Nikfam S, Albaji M, Vahedi S, Nasseri-Moghaddam S, Sharafkhah M, et al. Probiotic vs. Placebo in irritable bowel syndrome:a randomized controlled trial. Middle East J Dig Dis. 2013;5(2):98-102.
40. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbol DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol. 2013;48(10):1127-35.
41. Ko SJ, Han G, Kim SK, Seo JG, Chung WS, Ryu B, et al. Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. Evidence-based Complementary and Alternative Medicine. 2013;2013.
42. Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol. 2013;13(1):1.
43. Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol (Australia). 2014;29(1):52-9.
44. Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol. 2014;26(6):630-9.
45. Lorenzo-Zuniga V, Llop E, Suarez C, Alvarez B, Abreu L, Espadaler J, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709-16.
46. Ludidi S, Jonkers DM, Koning CJ, Kruimel JW, Mulder L, Vaart IB, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil. 2014;26(5):705-14. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/528/CN-00988528/frame.html.
47. Urgesi R, Casale C, Pistelli R, Rapaccini GL, De Vitis I. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2014;18(9):1344-53.
48. Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing bacillus coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench. 2014;7(3):156-63.
49. Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome - a 12 week double-blind study. Aliment Pharmacol Ther. 2014;40(1):51-62.
50. Wong RK, Yang C, Song GH, Wong J, Ho KY. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci. 2014;60(1):186-94.
51. Parkes GC, Sanderson JD, Whelan K. Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc. 2010;69(2):187-94.
52. Coffin B, Dapoigny M, Cloarec D, Comet D, Dyard F. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2004;28(1):11-5.
53. Spiegel B, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol. 2009;104(8):1984-91.
54. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7:30.